Extended versus bolus infusion of meropenem and piperacillin: A pharmacokinetic analysis

Minerva Anestesiologica

Volumn 80, Issue 12, 2014, Pages 1302-1309

  De Waele, J ^a   Carlier, M ^a   Hoste, E ^a   Depuydt, P ^a   Decruyenaere, J ^a   Wallis, S C ^b   Lipman, J ^b   Roberts, J A ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anti bacterial agents; Intensive care unit; Pharmacokinetics

Indexed keywords

CREATININE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; PIPERACILLIN; THIENAMYCIN DERIVATIVE;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; AGED; COHORT ANALYSIS; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED;

AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PIPERACILLIN; PROSPECTIVE STUDIES; THIENAMYCINS;

EID: 84920461871     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients - a systematic review of the pharmacokinetics of beta-Lactams. Crit Care 2011;15:R206.
2. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009:37:840-51; quiz 859.
3. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014;58:1072-83.
4. Kaufman SE, Donnell RW, Hickey WS. Rationale and evidence for extended infusion of piperacillin-tazobactam. Am J Health Syst Pharm 2011;68:1521-6.
5. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009;64:142-50.
6. Roberts JA, Kwa A, Montakantikul P, Gomersall C, Kuti JL, Nicolau DP. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region. Int J Antimicrob Agents 2011;37:225-9.
7. Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother 2011;66:343-9.
8. Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2009;34:429-33.
9. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 2007;27:1490-7.
10. Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sorgel F, Jones RN et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 2010;68:251-8.
11. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010;35:156-63.
12. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
13. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
14. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JP. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:2039-43.
15. Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol 2010;6:1017-31.
16. Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol 2011;12:2070-9.
17. Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J. Augmented renal clearance in the Intensive Care Unit: an illustrative case series. Int J Antimicrob Agents 2010;35:606-8.
18. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010;49:1-16.
19. Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M et al. Augmented creatinine clearance in traumatic brain injury. Anesth Analg 2010;111:1505-10.
20. Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care 2013;28:695-700.
21. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete AG, Hoste E et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 2013;17:R84.
22. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP et al. Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012;142:30-9.
23. Lipman J, Wallis SC, Boots RJ. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003;97:1149-54, table of contents.
24. Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012;73:27-36.
25. Carlier M, Stove V, Roberts JA, Van De Velde E, De Waele JJ, Verstraete AG. Quantification of seven beta-lactam antibiotics and two beta-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. Int J Antimicrob Agents 2012;40:416-422.
26. Briscoe SE, McWhinney BC, Lipman J, Roberts JA, Ungerer JP. A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2012;907:178-84.
27. Claus B, Buyle F, Robays H, Vogelaers D. Importance of infusion volume and pump characteristics in extended administration of beta-lactam antibiotics. Antimicrob Agents Chemother 2010;54:4950.